<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04295941</url>
  </required_header>
  <id_info>
    <org_study_id>039(C)WO19201</org_study_id>
    <nct_id>NCT04295941</nct_id>
  </id_info>
  <brief_title>Long-term Study With Trazodone Once-a-Day</brief_title>
  <official_title>Long-term Treatment With Trazodone Once-a-Day (TzOAD) in Patients With MDD: an Observational, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aziende Chimiche Riunite Angelini Francesco S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aziende Chimiche Riunite Angelini Francesco S.p.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present observational study is to assess the clinical response, functional
      impairment and quality of life in outpatients with Major Depressive Disorder who demonstrated
      an initial positive response to the acute treatment with Trazodone once-a-day monotherapy,
      for up to 24 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, prospective, single group, multicentre, international study.

      The present study is planned to assess, in a real-world setting, the long-term clinical
      response, functional impairment and quality of life in outpatients with Major Depressive
      Disorder who, according to the physician's judgment, have responded to the acute monotherapy
      (6 to 8 weeks of treatment) with Trazodone once-a-day and are eligible to continue Trazodone
      once-a-day monotherapy according to clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impression-improvement scale responders percentage</measure>
    <time_frame>24(+4) weeks</time_frame>
    <description>The clinical response expressed as CGI-I responders' percentage at 24 (+ 4) weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-improvement scale responders percentage</measure>
    <time_frame>12 (+ 3) weeks.</time_frame>
    <description>The clinical response expressed as CGI-I responders' percentage at 12 (+ 3) weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-improvement scale responders percentage</measure>
    <time_frame>18 (+ 3) weeks</time_frame>
    <description>The clinical response expressed as CGI-I responders' percentage at 18 (+ 3) weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Scale score</measure>
    <time_frame>24-week period</time_frame>
    <description>The functional impairment evaluated over the 24-week period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L Quality of life scale</measure>
    <time_frame>24-week period</time_frame>
    <description>The quality of life evaluated over the 24-week period</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">233</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Trazodone once-a-day treated patients</arm_group_label>
    <description>Major Depressive Disorder outpatients who, following an initial positive response to the acute treatment with Trazodone once-a-day monotherapy, will be eligible to enter the continuation therapy and will be observed up to 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TraZODone Hydrochloride 300 MG</intervention_name>
    <description>Oral administration of Trazodone once-a-day.</description>
    <arm_group_label>Trazodone once-a-day treated patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatients presenting with Major Depressive Disorder who, following an initial positive
        response to the acute treatment with Trazodone once-a-day monotherapy, will be eligible
        according to the physician's judgement, to enter the continuation therapy and will be
        observed up to 24 weeks.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male and female patients of any ethnic origin â‰¥18 years old at Baseline. Outpatients who
        meet the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 or the International
        Classification of Diseases (ICD)-10 criteria for MDD as their primary diagnosis and
        presenting with an episode of MDD.

        Patients judged as responders to the acute monotherapy with TzOAD after a minimum of 6 and
        a maximum of 8 weeks of treatment and who are eligible to continue the assigned monotherapy
        according to the physician's judgement.

        Patients legally capable of giving their written consent for participation in the study and
        for personal data processing and willing to comply with all study procedures.

        Exclusion Criteria:

        Patients that meet any of the contraindications to the administration of TzOAD according to
        the approved SmPC.

        Patients with previous or current diagnosis of bipolar disorder, schizophrenia or other
        psychotic disorder, dysthymic or adjustment disorders, mental retardation, organic mental
        disorders or mental disorders due to a general medical condition.

        Patients with previous or current history of a clinically significant neurological
        disorder, or any neurodegenerative diseases that might compromise the participation in the
        study.

        Patients who are, according to the physician's judgement, at serious risk of suicide.

        Patients with substance abuse or dependence (except nicotine dependence), as defined by
        DSM-5.

        Patients participating in any pharmacological or non-pharmacological interventional study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Annalisa Dr Bonelli</last_name>
    <phone>+ 39 06 91045364</phone>
    <email>annalisa.bonelli@angelinipharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandro Dr Comandini</last_name>
    <phone>+ 39 06 91045432</phone>
    <email>alessandro.comandini@angelinipharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Center Hera EOOD - Clinic/Outpatient Facility</name>
      <address>
        <city>Sofia</city>
        <zip>1510</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trazodone once-a-day</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Long term therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trazodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

